Positive reimbursement decision in Spain expands market access to include the five largest European markets Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed HNSA-5487: Phase 1 clinical study started in healthy volunteers LUND, Sweden, April 20, 2023…